The report highlights Alphamab Oncology's commitment to environmental, social, and governance (ESG) principles in 2021. Key achievements include the launch of Envafolimab, the world's first subcutaneously injected PD-L1 inhibitor, significant progress in clinical development of innovative bispecific antibody KN046, and the expansion of manufacturing capacity. The company also emphasizes on fostering a people-oriented and healthy workplace, ensuring safe production, and promoting a culture of compliance and integrity.
Issuing Company Alphamab Oncology
Report Type Sustainability Report
Report Language EN
Report Filesize 20.45 MB
No. of Pages 54 pages
Reporting periodJanuary 1, 2021-December 31, 2021
Report EditionUnknown
Assurance Provider Unknown
Reporting Standards GRI; SASB; UNSDGs
Materiality Assessmenttrue